8-KFiled Aug 12, 8:00 PM ET

Nektar Therapeutics Reports Q2 2026 Results

$NKTR · NEKTAR THERAPEUTICS

Research Summary

AI-generated summary of this SEC filing

Updated

Nektar Therapeutics Reports Q2 2026 Results

What Happened
Nektar Therapeutics announced its quarterly financial results on August 13, 2026, issuing a press release reporting results for the quarter ended June 30, 2026. The company furnished the press release as Exhibit 99.1 to its Form 8-K under Item 2.02 (Results of Operations and Financial Condition).

Key Details

  • Date of disclosure: August 13, 2026.
  • Reporting period: Quarter ended June 30, 2026.
  • Press release furnished as Exhibit 99.1 titled “Nektar Therapeutics Reports Second Quarter 2026 Results.”
  • The information is furnished (not “filed”) and therefore not subject to Section 18 liability or incorporation by reference into other SEC filings.

Why It Matters
This 8-K signals Nektar has publicly released its latest quarterly earnings and related financial information; investors should review the press release for revenue, earnings, cash position, guidance, or other metrics that could affect the stock. Note the company furnished the release (limited legal filing status), so check the actual press release or subsequent filings for full financial detail and any formal management discussion.